These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

492 related articles for article (PubMed ID: 14553864)

  • 1. Type 2 diabetes, cardiovascular risk, and the link to insulin resistance.
    Stolar MW; Chilton RJ
    Clin Ther; 2003; 25 Suppl B():B4-31. PubMed ID: 14553864
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Insulin resistance: from predisposing factor to therapeutic target in type 2 diabetes.
    Henry RR
    Clin Ther; 2003; 25 Suppl B():B47-63. PubMed ID: 14553866
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Progress with thiazolidinediones in the management of type 2 diabetes mellitus.
    Meriden T
    Clin Ther; 2004 Feb; 26(2):177-90. PubMed ID: 15038941
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Implications of rosiglitazone and pioglitazone on cardiovascular risk in patients with type 2 diabetes mellitus.
    Irons BK; Greene RS; Mazzolini TA; Edwards KL; Sleeper RB
    Pharmacotherapy; 2006 Feb; 26(2):168-81. PubMed ID: 16466323
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Management of co-existing diabetes mellitus and dyslipidemia: defining the role of thiazolidinediones.
    Florkowski CM
    Am J Cardiovasc Drugs; 2002; 2(1):15-21. PubMed ID: 14727995
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pioglitazone: an antidiabetic drug with the potency to reduce cardiovascular mortality.
    Pfützner A; Forst T
    Expert Opin Pharmacother; 2006 Mar; 7(4):463-76. PubMed ID: 16503818
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Rosiglitazone: potential beneficial impact on cardiovascular disease.
    Viberti GC
    Int J Clin Pract; 2003 Mar; 57(2):128-34. PubMed ID: 12661797
    [TBL] [Abstract][Full Text] [Related]  

  • 8. New oral therapies for type 2 diabetes mellitus: The glitazones or insulin sensitizers.
    Mudaliar S; Henry RR
    Annu Rev Med; 2001; 52():239-57. PubMed ID: 11160777
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Thiazolidinediones-benefits on microvascular complications of type 2 diabetes.
    Viberti G
    J Diabetes Complications; 2005; 19(3):168-77. PubMed ID: 15866064
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Thiazolidinediones in type 2 diabetes: a cardiology perspective.
    Khanderia U; Pop-Busui R; Eagle KA
    Ann Pharmacother; 2008 Oct; 42(10):1466-74. PubMed ID: 18698014
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Metformin and pioglitazone: Effectively treating insulin resistance.
    Staels B
    Curr Med Res Opin; 2006; 22 Suppl 2():S27-37. PubMed ID: 16914073
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Rationale for and role of thiazolidinediones in type 2 diabetes mellitus.
    Lebovitz HE
    Am J Cardiol; 2002 Sep; 90(5A):34G-41G. PubMed ID: 12231077
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Effects of thiazolidinediones on dyslipidemia in patients with type 2 diabetes. Are all equally vasoprotective?].
    Haberbosch W
    Herz; 2007 Feb; 32(1):51-7. PubMed ID: 17323035
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cardiovascular risk and cardiometabolic protection: role of glitazones.
    Petrazzi L; Grassi D; Polidoro L; D'Aurelio A; Croce G; Properzi G; Tiberti S; Desideri G; Ferri C
    J Nephrol; 2008; 21(6):826-35. PubMed ID: 19034866
    [TBL] [Abstract][Full Text] [Related]  

  • 15. EMPA-REG and Other Cardiovascular Outcome Trials of Glucose-lowering Agents: Implications for Future Treatment Strategies in Type 2 Diabetes Mellitus.
    Schernthaner G; Schernthaner-Reiter MH; Schernthaner GH
    Clin Ther; 2016 Jun; 38(6):1288-1298. PubMed ID: 27210264
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Peroxisome proliferator-activated receptor-gamma agonists in atherosclerosis: current evidence and future directions.
    Roberts AW; Thomas A; Rees A; Evans M
    Curr Opin Lipidol; 2003 Dec; 14(6):567-73. PubMed ID: 14624133
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pleiotropic effects of thiazolidinediones: implications for the treatment of patients with type 2 diabetes mellitus.
    Defronzo RA; Mehta RJ; Schnure JJ
    Hosp Pract (1995); 2013 Apr; 41(2):132-47. PubMed ID: 23680744
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The role of the thiazolidinediones in the practical management of patients with type 2 diabetes and cardiovascular risk factors.
    Edelman SV
    Rev Cardiovasc Med; 2003; 4 Suppl 6():S29-37. PubMed ID: 14668701
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pleiotropic effects of thiazolidinediones.
    Rizos CV; Liberopoulos EN; Mikhailidis DP; Elisaf MS
    Expert Opin Pharmacother; 2008 May; 9(7):1087-108. PubMed ID: 18422468
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effects of thiazolidinediones on cardiovascular risk factors.
    Gouda BP; Asnani S; Fonseca VA
    Compr Ther; 2002; 28(4):200-6. PubMed ID: 12506489
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 25.